Clinical trials: Stage IV Ovarian Cancer
Ovarian Cancer
Radiolabeled Folic Acid and Imaging to Detect Ovarian Cancer
RATIONALE: Diagnostic procedures using the drug radiolabeled folic acid and imaging may be effective in detecting ovarian cancer.
- Trial name
- NCT00003763
- Testing
- radionuclide imaging, indium In 111 folic acid
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Endocyte
Gastric Adenocarcinoma, Esophageal Cancer
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
The primary objective in Phase I is to evaluate the safety and tolerability of sacituzumab govitecan-hziy (SG) as a single agent administered in 21-day treatment cycles in previously treated participants with advanced epithelial…
- Conditions
- Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT01631552
- Testing
- Sacituzumab Govitecan-hziy (SG)
- Where
- 12 sites in United States
- Volunteers
- 515 people
- Sponsor
- Gilead Sciences
Platinum-resistant Ovarian Cancer
Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)
The purpose of the study is to identify the optimal dose level of NP-G2-044 in combination with standard of care (SOC) pegylated liposomal doxorubicin (PLD), and to compare the efficacy and safety of NP-G2-044+PLD vs.
- Trial name
- NCT07109414
- Testing
- NP-G2-044, PLD
- Where
- 6 sites in United States
- Volunteers
- 380 people
- Sponsor
- Novita Pharmaceuticals, Inc.
Stage III Ovarian Carcinoma, Stage IV Ovarian Carcinoma
Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas
This is a double-blind study in which approximately 99 study patients will be randomized in a 2:1 ratio to receive either AVOVA-1 or MC.
- Conditions
- Stage III Ovarian Carcinoma, Stage IV Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
- Trial name
- NCT02033616
- Testing
- AVOVA-1, MC
- Where
- 6 sites in United States
- Volunteers
- 99 people
- Sponsor
- Aivita Biomedical, Inc.
Epithelial Ovarian Cancer
Treatment of Paclitaxel Plus Carboplatin Followed by Gemcitabine Plus Carboplatin for Patients With Epithelial Ovarian Cancer
The purpose of this study is to evaluate the efficacy of paclitaxel and carboplatin followed by gemcitabine and carboplatin therapy for patients with epithelial ovarian cancer.
- Trial name
- NCT00490711
- Testing
- gemcitabine, carboplatin, paclitaxel
- Where
- Slovakia
- Volunteers
- 7 people
- Sponsor
- Eli Lilly and Company
Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to…
- Conditions
- Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT06084481
- Testing
- ABBV-400, Itraconazole (ITZ), Bevacizumab
- Where
- 54 sites in United States, Australia and 6 more
- Volunteers
- 325 people
- Sponsor
- AbbVie
Ovarian Neoplasm
Phase II CT-2103/Carboplatin in Ovarian Cancer
The purpose of this study is to evaluate the safety and efficacy of CT-2103 (poly(L)glutamate-paclitaxel) in combination with carboplatin for the treatment of patients with Stage III or IV ovarian or primary peritoneal cancer.
- Trial name
- NCT00069901
- Testing
- CT-2103 (poly(L)glutamate-paclitaxel), carboplatin
- Where
- 17 sites in United States
- Volunteers
- 82 people
- Sponsor
- CTI BioPharma
Fallopian Tube Cancer, Ovarian Cancer
Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DX-8951f in treating patients who have recurrent…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00004060
- Testing
- exatecan mesylate
- Where
- United States
- Sponsor
- Daiichi Sankyo
Cancer
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00101972
- Testing
- monoclonal antibody RAV12
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- MacroGenics
Cancer, Carcinoma
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
This study is a 2 part, 2 cohort, open-label, dose escalation/de escalation study of AMG 386 in combination with either pegylated liposomal doxorubicin or topotecan in subjects with recurrent ovarian cancer.
- Conditions
- Cancer, Carcinoma, Fallopian Tube Cancer, Gynecological Malignancies
- Trial name
- NCT00770536
- Testing
- A1: AMG 386 10 mg/kg + Liposomal doxorubicin, A3: AMG 386 15mg/kg + Liposomal doxorubicin, B1: AMG 386 10 mg/kg + Topotecan
- Where
- 16 sites in United States, Australia and 1 more
- Volunteers
- 103 people
- Sponsor
- Amgen
Metastatic Ovarian Cancer, Triple Negative Breast Cancer
Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer
This is a Phase 1b, open-label, non-randomized, Dose Confirmation study. Subjects will be treated, once a week, with IV doses of Nerofe and low dose (20 mg/m2) Doxorubicin (6-8 hours from one another) in consecutive, 28-day…
- Trial name
- NCT03634150
- Testing
- Nerofe is a first in class derivative of a human hormon-peptide(TCApF), with Cancer suppressive properties.
- Where
- Israel
- Sponsor
- Immune System Key Ltd
Fallopian Tube Cancer, Peritoneal Neoplasms
OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer
The purpose of this project is to see if weekly carboplatin compared with phenoxodiol in combination with weekly carboplatin, is effective against late stage ovarian cancer and to see what, if any, side-effects of treatment may…
- Conditions
- Fallopian Tube Cancer, Peritoneal Neoplasms, Ovarian Cancer
- Trial name
- OVATURE (NCT00382811)
- Testing
- phenoxodiol, carboplatin
- Where
- 70 sites in United States, Australia and 5 more
- Volunteers
- 142 people
- Sponsor
- MEI Pharma, Inc.
Fallopian Tube Cancer, Ovarian Cancer
Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00003634
- Testing
- oregovomab
- Where
- 46 sites in United States, Canada
- Volunteers
- 400 people
- Sponsor
- AltaRex
Ovarian Cancer
Sequential Chemotherapy in Treating Patients With Residual Disease Following Surgery for Stage IIB, Stage III, or Stage IV Ovarian Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy drugs in different ways may kill more tumor cells.
- Trial name
- NCT00003733
- Testing
- carboplatin, paclitaxel, topotecan hydrochloride
- Where
- 2 sites in United Kingdom
- Volunteers
- 40 people
- Sponsor
- SmithKline Beecham
Epithelial Ovarian Cancer, Primary Peritoneal
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance treatment following response to front-line treatment in newly diagnosed ovarian…
- Conditions
- Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Newly Diagnosed
- Trial name
- ATHENA (NCT03522246)
- Testing
- Rucaparib, Nivolumab
- Where
- 238 sites in United States, Australia and 22 more
- Volunteers
- 1,097 people
- Sponsor
- pharmaand GmbH
Advanced or Metastatic Hepatocellular Cancer, Advanced or Metastatic Ovarian Cancer
A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers
This was an exploratory proof of concept study to determine the clinical activity of tasquinimod in patients with advanced or metastatic hepatocellular carcinoma, ovarian carcinoma, renal cell carcinoma and gastric carcinoma who…
- Conditions
- Advanced or Metastatic Hepatocellular Cancer, Advanced or Metastatic Ovarian Cancer, Metastatic Renal Cell Cancer, Advanced or Metastatic Gastric Carcinoma
- Trial name
- NCT01743469
- Testing
- Tasquinimod
- Where
- 24 sites in Belgium, Canada and 3 more
- Volunteers
- 201 people
- Sponsor
- Ipsen
Fallopian Tube Cancer, Ovarian Cancer
Weekly Infusions of Paclitaxel in Treating Women With Stage III or Stage IV Ovarian Cancer Refractory to Paclitaxel and Platinum
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different ways may kill more tumor cells.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00003160
- Testing
- paclitaxel
- Where
- 18 sites in United States
- Volunteers
- 100 people
- Sponsor
- Theradex
Ovarian Cancer
A Study of Bevacizumab (Avastin) in Neoadjuvant Therapy in Participants With International Federation of Gynecology and Obstetrics (FIGO) Stage IIIC/IV Ovarian, Tubal, or Peritoneal Cancer, Initially Unresectable
This randomized, open-label study will evaluate the efficacy and safety of neoadjuvant bevacizumab in participants with initially unresectable, FIGO stage IIIC/IV ovarian, tubal, or peritoneal cancer.
- Trial name
- ANTHALYA (NCT01739218)
- Testing
- Carboplatin, Paclitaxel, Bevacizumab
- Where
- 15 sites in France
- Volunteers
- 99 people
- Sponsor
- Hoffmann-La Roche
Ovarian Cancer, Fallopian Tube Cancer
HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
HS-20089 is an investigational antibody-drug conjugate (ADC) composed of a humanized IgG1 anti-B7-H4 monoclonal antibody conjugated to the topoisomerase I inhibitor payload via a protease-cleavable linker, with an average…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer
- Trial name
- NCT06014190
- Testing
- HS-20089
- Where
- 28 sites in China
- Volunteers
- 460 people
- Sponsor
- Hansoh BioMedical R&D Company
Tumors, Glioma
A Phase I Study of ECO-4601 in Patients With Advanced Cancer
The purpose of this study was to determine the maximum tolerated dose (MTD) and the recommended dose for future studies of ECO-4601 administered as a continuous IV infusion for 14 days with 7 days recovery (21 day cycle) in…
- Conditions
- Tumors, Glioma, Colorectal Cancer, Lung Cancer
- Trial name
- NCT00338026
- Testing
- ECO-4601
- Where
- 2 sites in Canada
- Volunteers
- 26 people
- Sponsor
- Thallion Pharmaceuticals